Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
about
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo.Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.Ponatinib in the therapy of chronic myeloid leukemia.Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic MetabolitesAssessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Cardiovascular toxic effects of targeted cancer therapy.Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylationRole of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
P2860
Q30241189-FA5782D5-686A-43A7-8C0F-018DA8AC22C5Q30242015-C689E886-3FE8-4107-88ED-31B22F1D7D5CQ37701501-47D9E4A6-ED50-4910-980C-45F2E7C895ADQ38389475-CF8EBD07-CF78-4970-A54A-ACB72CD4813EQ38623810-907A0957-45CC-4B57-8DFD-0D5C7F2CC34CQ38945162-55D5D211-CBF9-4C29-9302-BBA641A4EAFCQ41348012-F61D258A-DC8A-4D5E-9C35-276249931D8FQ41651460-687D47C9-9CFE-48BA-A8E7-89773147F1ECQ47096076-420B5FEE-BAC4-449A-9877-72E851EC8C64Q47706936-5614855B-304E-4BB3-A62A-053CFE3918F6Q47917650-94177907-2F82-47CB-BE79-3503AFF0AFDCQ49887884-593DFFED-E309-4783-B979-45280458A7FCQ52567954-90683E5F-FF2B-45AA-9AF2-173A2397B7B4Q52641875-D1E27F50-B077-4066-AC43-0857DB6386CEQ53276936-5F678870-0A62-493A-9A5E-3B0212D1D0BDQ58761411-50AB3F03-E7E4-4E94-88B7-05F34D048985Q58788266-BCBB355B-0071-47D8-A0C4-4F3A35ACD84F
P2860
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Ponatinib versus imatinib for ...... ed, open-label, phase 3 trial.
@ast
Ponatinib versus imatinib for ...... ed, open-label, phase 3 trial.
@en
type
label
Ponatinib versus imatinib for ...... ed, open-label, phase 3 trial.
@ast
Ponatinib versus imatinib for ...... ed, open-label, phase 3 trial.
@en
prefLabel
Ponatinib versus imatinib for ...... ed, open-label, phase 3 trial.
@ast
Ponatinib versus imatinib for ...... ed, open-label, phase 3 trial.
@en
P2093
P50
P1433
P1476
Ponatinib versus imatinib for ...... ed, open-label, phase 3 trial.
@en
P2093
Agnès Guerci-Bresler
Charles Chuah
David Andorsky
David Simpson
EPIC investigators
Franck E Nicolini
Frank G Haluska
Gabriel Etienne
Jeffrey H Lipton
Leif Stenke
P304
P356
10.1016/S1470-2045(16)00080-2
P50
P577
2016-04-12T00:00:00Z